BAROREFLEX THERAPY FOR DISORDERED BREATHING

• US 20100249874A1
• Filed: 05/21/2010
• Published: 09/30/2010
• Est. Priority Date: 09/27/2000
• Status: Abandoned Application

• Current Assignee: CVRx, Inc.
• Original Assignee: CVRx, Inc.
• Inventors: Bolea, Stephen L., Keith, Peter T., Serdar, David J., Persson, Bruce J., Rossing, Martin A., Kieval, Robert S., Irwin, Eric D.
• Application Number:
  US12/785,287
• Publication Number:
  US 20100249874A1
• Time in Patent Office: Days
• US Class Current: 607/42
• CPC Class Codes: A61N 1/0556 Cuff electrodes
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/36117 for treating hypertension

Abstract

Devices, systems and methods are described by which the blood pressure, nervous system activity, and neurohormonal activity may be selectively and controllably reduced by activating baroreceptors. A baroreceptor activation device is positioned near a baroreceptor, preferably a baroreceptor located in the carotid sinus. A control system may be used to modulate the baroreceptor activation device. The control system may utilize an algorithm defining a stimulus regimen which promotes long term efficacy and reduces power requirements/consumption. The baroreceptor activation device may utilize electrodes to activate the baroreceptors. The electrodes may be adapted for connection to the carotid arteries at or near the carotid sinus, and may be designed to minimize extraneous tissue stimulation.

Claims

1. A disordered breathing therapy method, comprising:

delivering a plurality of therapies to treat disordered breathing, including at least a first therapy utilizing electrical stimulation that modulates a patient'"'"'s baroreflex response, and including a second therapy different from the first therapy;

sensing one or more conditions associated with the patient;

determining, from the one or more sensed conditions, an efficacy of at least one therapy of the first and second therapies in treating disordered breathing;

determining, from the one or more sensed conditions, an impact on the patient other than the efficacy of the at least one therapy; and

modifying the at least one therapy if the efficacy is determined to be acceptable and the impact is determined to be unacceptable.

2. The method of claim 1, wherein the modifying includes shifting from the first to the second therapy.

3. The method of claim 1, wherein the delivering, sensing, and modifying steps are provided at least in part by an implantable device, wherein the impact on the patient relates to a service life of the implantable device, and wherein the modifying is carried out to enhance the service life of the implantable device.

4. A disordered breathing therapy system at least a portion of which is adapted for implantation in a patient, the system comprising:

a plurality of therapy devices, each therapy device configured to deliver a disordered breathing therapy different from disordered breathing therapies delivered by other therapy devices;

a plurality of sensors capable of sensing at least one condition associated with the patient; and

a control system coupled to the plurality of therapy devices and to the plurality of sensors, the control system configured to;

determine from the at least one condition an efficacy of at least one therapy of the disordered breathing therapies in treating disordered breathing;

determine from the at least one condition an impact on the patient other than the efficacy of the at least one therapy; and

modify the at least one therapy if the efficacy is determined to be acceptable and the impact is determined to be unacceptable;

wherein at least one of the therapy devices includes a baroreflex stimulator configured to deliver an electrical stimulation therapy modifying the patient'"'"'s baroreflex response.

5. The system of claim 4, wherein at least the baroreflex stimulator and the control system are adapted for implantation in the patient.

6. The system of claim 4, wherein at least the baroreflex stimulator and the control system are part of an implantable device, and wherein the impact on the patient relates to a service life of the implantable device, and wherein the control system is adapted to enhance the service life of the implantable device.